PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Praxis Precision Medicines, Inc. (PRAX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Profitability (D). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | C+ (2.8) | D (1.3) | C (2.2) | C+ (2.6) | C (2.3) |
| 2026-11-07 | C+ (2.5) | B- (3.0) | D (1.4) | C (2.3) | C+ (2.7) | C (2.4) |
| 2026-10-31 | C+ (2.5) | B- (2.9) | D (1.4) | C+ (2.7) | C+ (2.7) | C (2.4) |
| 2026-10-24 | C+ (2.5) | C+ (2.8) | D (1.4) | C (2.3) | C+ (2.6) | C (2.3) |
| 2026-10-17 | C+ (2.5) | B- (2.9) | D (1.4) | C (2.4) | C+ (2.6) | C (2.4) |